Search for: "Par Pharmaceutical"
Results 1 - 20
of 303
Sort by Relevance
|
Sort by Date
26 Feb 2024, 1:36 am
As the EBA pointed out in par. 95 of Decision G 0002/21, it is a rather abstract test. [read post]
17 Oct 2023, 3:40 pm
More from our authors: Vissers Annotated European Patent Convention 2023 Edition by Kaisa Suominen, Nina Ferara, Peter de Lange, Andrew Rudge€ 105 Guide to EU and UK Pharmaceutical Regulatory Law, Eig [read post]
26 Sep 2023, 3:11 am
Accordingly, the BRPTO is trying to hit a target of deciding cases within 24 months from filing “on par with the best international practices and will benefit its users”. [read post]
3 Aug 2023, 3:03 am
More from our authors: Guide to EU and UK Pharmaceutical Regulatory Law, Eighth Edition by Sally Shorthose€ 265 Genuine Use of Trademarks, Second Edition by Eléonore Gaspar€ 190 [read post]
23 Mar 2023, 10:37 am
.); and 3. a functional factor for the identification of the data holders who should make health data available for secondary use (Recital 40 EHDS and Art. 33 par. 3 EHDS). [read post]
9 Jan 2023, 9:01 pm
The settlement ranks among the five largest securities settlements ever paid by a pharmaceutical manufacturer. [read post]
5 Jan 2023, 2:22 pm
The settlement ranks among the five largest securities settlements ever paid by a pharmaceutical manufacturer. [read post]
30 Sep 2022, 12:40 pm
Consequently, such companies will be treated on par with other Indian companies, and will be subject to less regulation. [read post]
24 Aug 2022, 4:00 am
If behaviour management means using the litigation process to give a defendant and other defendants an education of their responsibilities and is something more or different than just punishment for bad behaviour, the pharmaceutical companies are already heavily regulated and do not need an education about their legal responsibilities by a class action that will yield little to no compensation for the overwhelming majority of the class and ends up being little more than a licensing fee for… [read post]
21 Aug 2022, 9:11 pm
Eagle Pharmaceuticals, Inc. [read post]
19 Aug 2022, 11:15 am
This week in Other Barks & Bites: the Federal Circuit rules that Eagle Pharmaceutical’s ANDA defines a product that does not infringe upon Par Pharmaceutical’s patents covering Vasostrict; an inventor amicus brief in the OpenSky IPR asks USPTO Director Vidal to mandate sanctions for abuse of PTAB process; the Seventh Circuit affirms a default judgment against a Chinese counterfeiter of sports merchandise after finding personal jurisdiction over the… [read post]
19 Aug 2022, 11:15 am
This week in Other Barks & Bites: the Federal Circuit rules that Eagle Pharmaceutical’s ANDA defines a product that does not infringe upon Par Pharmaceutical’s patents covering Vasostrict; an inventor amicus brief in the OpenSky IPR asks USPTO Director Vidal to mandate sanctions for abuse of PTAB process; the Seventh Circuit affirms a default judgment against a Chinese counterfeiter of sports merchandise after finding personal jurisdiction over the… [read post]
18 Aug 2022, 11:39 am
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
18 Aug 2022, 11:39 am
’s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC (collectively, Par). [read post]
2 Jun 2022, 7:01 am
The boss said Owens’ performance was sub-par. [read post]
20 Mar 2022, 4:42 pm
I, 2e éd. 2016, no 1884 ; par analogie : arrêt du TAF B-6637/2014 du 10 octobre 2016 consid. 3.1.2 "sensationail [fig.] [read post]
4 Jan 2022, 10:33 am
A Pennsylvania federal judge ordered California to pay nearly $80,000 in legal fees to Par Pharmaceutical Inc for failing to comply with discovery obligations in multidistrict litigation alleging a broad price-fixing conspiracy for generic drugs. [read post]
4 Jan 2022, 10:33 am
A Pennsylvania federal judge ordered California to pay nearly $80,000 in legal fees to Par Pharmaceutical Inc for failing to comply with discovery obligations in multidistrict litigation alleging a broad price-fixing conspiracy for generic drugs. [read post]
18 Nov 2021, 3:58 am
Though it is remarkable to have so many leaders engaged in this way, it is also par for the course in Utah. [read post]
11 Nov 2021, 10:08 am
Par Pharmaceutical, Inc., 694 F.3d 1344 (Fed. [read post]
